Drug Profile

CS 3003

Alternative Names: CS3003

Latest Information Update: 28 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CStone Pharmaceuticals
Class Antineoplastics; Small molecules
Mechanism of Action HDAC6 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Multiple myeloma; Solid tumours

Most Recent Events

28 Jan 2023 No recent reports of development identified for preclinical development in Multiple-myeloma in China
28 Jan 2023 No recent reports of development identified for preclinical development in Solid-tumours in China
22 Jun 2020 Pharmacodynamics data from a preclinical trial in Solid tumours and Multiple myeloma presented at the 111^th Annual Meeting of the American Association for Cancer Research (AACR-2020)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com